先天性心脏病患者Ferumoxytol增强全心MRI剂量优化
该前瞻性研究纳入45例先天性心脏病患者,在1.5T下行Ferumoxytol增强3D全心MRI,采用序贯剂量方案(1→2或2→3 mg/kg)。结果显示1-3 mg/kg各剂量间图像质量、右冠状动脉长度、对比噪声比及诊断完整性无显著差异。心肌与血池nulling TI随剂量增加显著缩短,且TI变化呈非线性饱和模式。
要点
- 1-3 mg/kg剂量下均可获得诊断质量的3D全心图像,低剂量方案可行
- 血池nulling TI在首剂后可预测二次给药后的TI变化,有助于个体化调整扫描参数
- 1 mg/kg时心肌nulling TI可能延长并侵入收缩期静息期,需注意采集窗口设置
核心结论
- Ferumoxytol增强3D全心MRI在1-3 mg/kg剂量范围内均可提供诊断质量评估
- 剂量依赖性TI缩短遵循非线性饱和模式,支持优化低剂量方案
研究设计与样本
- 前瞻性研究,纳入45例先天性心脏病患者,1.5T磁共振行Ferumoxytol增强3D全心MRI
- 采用序贯剂量递增方案:1 mg/kg→2 mg/kg或2 mg/kg→3 mg/kg
- 使用Look-Locker序列测量血池与心肌nulling TI,采用基线校正变化评分回归及混合效应ANCOVA分析
关键影像表现/征象
- 各剂量间右冠状动脉图像质量、可见长度、对比噪声比及心腔大血管图像质量无显著差异
- 1 mg/kg时心肌nulling TI延长可能侵入收缩期静息期,影响冠状动脉显示
诊断标准与关键数值
- 各剂量间对比噪声比、右冠状动脉长度、图像质量及诊断完整性均无显著差异(均P>0.05)
- 心肌与血池nulling TI随剂量递增显著缩短(P≤0.02)
- 二次给药后血池TI变化可由首次给药后TI强烈预测(β=-0.63,P<0.001)
- 起始剂量(1或2 mg/kg)与TI变化无关(P=0.70)
临床应用与阅片要点
- 临床可使用1 mg/kg低剂量Ferumoxytol获得诊断质量3D全心图像,降低药物暴露
- 可根据首次给药后测得的血池TI预测后续TI变化,个体化设置反转时间
- 使用1 mg/kg剂量时需警惕心肌nulling TI延长干扰收缩期冠状动脉成像
局限性
- 原文未明确说明盲法评估及观察者间一致性情况
- 单中心研究,未报告不同场强或不同序列下的验证结果
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Ferumoxytol is used off-label as a contrast agent for cardiovascular magnetic resonance (CMR). However, the dose-response relationship between ferumoxytol, longitudinal relaxation, and image quality in pediatric and young patients remains unclear.
OBJECTIVE: To evaluate the effects of sequential ferumoxytol dose escalation on three-dimensional (3D) whole-heart (WH) image quality and blood-pool nulling inversion time (TI), a physiologic surrogate of post-contrast T1 shortening.
MATERIALS AND METHODS: In this prospective study, 45 patients with congenital heart disease underwent ferumoxytol-enhanced 3D WH CMR at 1.5 T using sequential dose regimens (1 mg/kg→2 mg/kg or 2 mg/kg→3 mg/kg). Right coronary artery (RCA) image quality and visible length, contrast-to-noise ratio (CNR), and image quality of the cardiac chambers and great vessels, as well as diagnostic completeness, were assessed. Blood-pool and myocardial nulling TI were measured using Look-Locker sequences. Baseline-adjusted change-score regression was the primary analysis, with mixed-effects ANCOVA performed to model TI behavior while accounting for repeated within-patient measurements.
RESULTS: No significant differences were observed in CNR, RCA length, image quality, or diagnostic completeness between all doses (all P>0.05). Myocardial and blood-pool nulling TI shortened significantly with dose escalation (P≤0.02). Change in blood-pool TI after the second dose was strongly predicted by TI after the first dose (β=-0.63, P<0.001), whereas starting dose (1 mg/kg or 2 mg/kg) was not associated with TI change (P=0.70). At 1 mg/kg, prolonged myocardial nulling TI may encroach upon the systolic rest period.
CONCLUSIONS: Ferumoxytol-enhanced 3D WH imaging provides diagnostic-quality assessment across 1-3 mg/kg dosing. Dose-dependent TI shortening follows a nonlinear, saturating pattern, supporting optimized low-dose protocols.
引用
- Erdem, Hussain, El Jerbi, et al. Ferumoxytol dose optimization for three-dimensional whole-heart magnetic resonance imaging in patients with congenital heart disease. Pediatr Radiol. 2026. PMID: 42412190. doi:10.1007/s00247-026-06706-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。